Studies | Type | Participants | Mean level of 25(OH)D at baseline [mean (SD)] or [median (IQR)] | Age | Mean age | Sex (girl/female) | Interventions | Treatment period | Observational period |
---|---|---|---|---|---|---|---|---|---|
Gestational period | |||||||||
Litonjua et al., 2016 [18] | randomized, double-blind, placebo-controlled study | 876 women with asthma, eczema or allergic rhinitis history (or in the biological father) 806 children | I: 23.3 (10.1) ng/mL C: 22.5 (10.1) ng/mL | 18 – 39 years | I: 27.5 C: 27.3 | I: 51% C: 45% | I: 4000 IU/d of vitamin D plus a prenatal vitamin containing 400 IU vitamin D C: placebo plus a prenatal vitamin containing 400 IU of vitamin D | pregnancy | asthma and wheezing were diagnosed in children up to 3 years of age |
Chawes et al., 2016 [19] | randomized, double-blind, placebo-controlled study | 581 healthy women | I: 31 (10) ng/mL C: 31 (10) ng/mL | NA | I: 32.5 C: 32.0 | NA | I: 2400 IU/d plus a prenatal vitamin containing 400 IU of vitamin D C: placebo plus a prenatal vitamin containing 400 IU of vitamin D | pregnancy week 24 to 1 week postpartum | asthma and wheezing were diagnosed in children up to 3 years of age |
Litonjua et al., 2020 [20] | a randomized, double-blind, placebo-controlled trial | 876 women with asthma, eczema or allergic rhinitis history (or in the biological father) 806 children | I: 23.3 (10.3) ng/mL C: 22.6 (10.2) ng/mL | 18 – 39 years | I: 27.5 C: 27.2 | I: 50.5% C: 45.1% | I: 4000 IU/d of vitamin D plus a prenatal vitamin containing 400 IU of vitamin D C: placebo plus a prenatal vitamin containing 400 IU of vitamin D | pregnancy | asthma and wheezing were diagnosed in children up to 6 years of age |
Infantile period | |||||||||
Rosendahl et al., 2019 [15] | randomized, double blinded controlled trial | 975 infants | Cord blood 30 µg: 81.3 (24) nmol/L 10 µg: 81.7 (28) nmol/L | from the age of 2 weeks | - | I: 50% C: 50% | 30 µg: 1200 IU/d of vitamin D 10 µg: 400 IU/d of vitamin D | from 2 weeks to 24 months of age | asthma and wheezing were diagnosed up to 12 months of life |
Rueter et al., 2020 [21] | randomized, double-blinded controlled trial | 195 infants | Cord blood I: 67.8 (17.5) nmol/L C: 61.1 (14.2) nmol/L | before 28 days of age | I: 13.2 C: 12.8 days at randomization | I: 47.4% C: 45.9% | I: 400 IU/d of vitamin D3 C: placebo | for the first six months of life | asthma and wheezing were diagnosed up to 2.5 years of age |
Hibbs et al., 2018 [22] | masked placebo-controlled randomized clinical trial | 300 infants | I: 19.1 (15.7–28.0) ng/mL C: 21.0 (17.0–25.0) ng/mL | NA | I: 11 C: 13 days at randomization | I: 49.7% C: 39% | I: 400 IU/d of cholecalciferol C: placebo | until 6 months of age | asthma and wheezing were diagnosed up to 12 months of life |
Rueter et al., 2019 [23] | a double-blind, placebo-controlled RCT | 195 inflants | NA | before 28 days of age | I: 13.2 C: 12.8 days at randomization | I: 47.4% C: 45.9% | I: 400 IU/d of vitamin D3 C: placebo | for the first six months of life | wheezing was diagnosed up to 3 and 6 months of age |
Childhood period | |||||||||
Thakur et al., 2021 [24] | placebo‐controlled, blinded, randomized controlled trial | 60 children with moderate persistent asthma | I: 15.8 (8.2) ng/mL C: 16.5 (9.9) ng/mL | 6 – 11 years | I: 9 C: 8.7 | I: 46.6% C: 40% | I: 2000 IU/d of vitamin D C: placebo + budesonide 400 μg and formoterol 24 μg daily | 3 months | the C‐ACT score and FEV1 were measured at baseline and after 3 months |
Jat et al., 2021 [14] | double-blind, randomized controlled trial | 250 asthmatic children | I: 11.6 (4.6) ng/ml C: 10.8 (4.4) ng/ml | 4 – 12 years | I: 8.2 C: 7.8 | I: 71.2% C: 72.8% | I: 1000 IU/d of vitamin D C: placebo | 9 months | the C‐ACT score and FEV1 were measured at baseline and after 9 months |
Kerley et al., 2016 [25] | a double-blind, randomized, PL-controlled trial | 44 children with asthma | I: 58 (39–69) (nmol/l) C: 51 (39–64) (nmol/l) | 6–16 years | I: 10 C: 7 | I: 35% C: 41% | I: 2000 IU/d of vitamin D3 C: placebo | 15 weeks | the C‐ACT score and FEV1 were measured at baseline and after 15 weeks |
Adulthood period | |||||||||
Emami Ardestani et al., 2020 [26] | randomized, controlled clinical trial | 132 mild-to-moderate asthma patients with vitamin D insufficiency and deficiency | Insufficient group I: 23.42 (2.64) ng/ml C: 23.64 (3.26) ng/ml Deficient group I: 11.29 (0.79) ng/ml C: 11.36 (0.75) ng/ml | above 18 years old | I: 42.77 C: 41.00 | Insufficient group I: 33.3% C: 57.6% Deficient group I: 51.5% C: 39.4% | Insufficient group I: 1000 U/d of vitamin D C: placebo Deficient group I: 50,000 U/week of vitamin D to achieve serum 25(OH)D level > 20 ng/ml; followed by a maintenance dose of 1000 U/d C: placebo + asthma controller (Symbicort) | 3 months | the ACT score and FEV1 were measured at baseline and after 3 months |
Andújar-Espinosa et al., 2021 [27] | randomized, triple-blind, placebo-controlled, parallel-group study | 112 adult asthmatic patients | I: 16.71 (6.71) ng/mL C: 17.48 (5.72) ng/mL | above 18 years old | I: 54.57 C: 56.61 | I: 71.4% C: 83.9% | I: 16,000 IU/week of calcifediol C: placebo + usual asthma treatment | 6 months | the ACT score and FEV1 were measured at baseline and after 6 months |
Ali et al., 2017 [28] | an open-label prospective randomized controlled trial | 82 patients with asthma | I: 18 (3.7–45) ng/mL C: 18.5 (3.5–54.7) ng/mL | 18 to 65 years old | I: 43 C: 48 | I: 62.8% C: 74.4% | I: 1 µg/d of alfacalcidol C: standard asthma treatment Vental inhaler as needed + Vental Compositum (mild asthma) + Foradil Aerolizer or Uniphyllin (moderate asthma) Higher dose of Beclomethasone or Prednisolone added (severe asthma) | 4 months | FEV1 was measured at baseline and after 4 months |
Martineau et al., 2015 [29] | a prospective randomized, placebo controlled, triple-blind study | 250 adults with asthma | I: 49.8 (25.2) nmol/L C: 49.4 (24.2) nmol/L | 16 to 80 years old | I: 49.4 C: 46.4 | I: 56% C: 57% | I: 120 000 IU/2 months of vitamin D3 (Vigantol oil) C: placebo | 12 months | the ACT score and FEV1 were measured at baseline and after 12 months |
Nageswari et al., 2014 [30] | an open labeled, randomized comparative trial | 68 patients with asthma | NA | 35 to 65 years | I: 57.26 C: 56.23 | I: 18% C: 16% | I: 1000 IU/d of vitamin D3 + Budesonide 400 μg + formoterol 24 μg C: Budesonide 400 μg + formoterol 24 μg | 90 days | FEV1 was measured at baseline and after 90 days |